Monitoring Registers |
Italian Medicines Agency
Aifa toggle bar Search
Search keywords
The Agency
The Agency
Mission and values
Organisation
Scientific and Economic Committee for Medicines
Support and Coordination Secretariats and Advisory Committees
International Collaborations
EU Projects
Legislation
Forms
Competition notices
Resolutions
Tenders and contracts
Quality assurance
Guarantee Committee
Atti di notifica
Associazioni dei pazienti
AIFA Incontra
Contacts
Certified email
COVID-19
COVID-19
Communications about COVID-19
COVID-19 Vaccines
Medicines usable for treatment of COVID-19 disease
Use of monoclonal antibodies for COVID-19
Use of antivirals for COVID-19
Monitoring of medicinal products used during the COVID-19 epidemic
Clinical Trials - COVID-19
Compassionate Use Programs - COVID-19
Access to medicinal products
Access to medicinal products
Early access and off-label use
Authorisation of medicinal products
Medicine shortages
Antibiotic medicinal products
Biological medicinal products
Vaccines
Blood derivatives
Generic medicinal products
Biosimilar medicinal products
Orphan medicinal products
Advanced therapies
Homeopathic medicinal products
Allergens
Medicinali di origine vegetale
Ancillary medicinal substances incorporated in medical devices
Safety of medicinal products
Safety of medicinal products
Pharmacovigilance
National Pharmacovigilance Network
Adverse Reactions to medicinal products
Persons in charge of Pharmacovigilance
European Eudravigilance System
Accesso alle segnalazioni - ADRreports
Regional pharmacovigilance funds
Segnali di sicurezza
Risk management measures
Medicinal products subject to additional monitoring
Quality and Inspections
Quality and Inspections
Quality defects
Inspections and authorisations
Qualified person
Fight of pharmaceutical crime
Research and Clinical trials
Research and Clinical trials
Clinical trials concerning medicinal products
EU Regulation on Clinical trials
National Observatory on Clinical Trials
Registro Studi Osservazionali
Comitati Etici Nazionali (CEN)
Ethics Committees Coordination Centre
Independent clinical research
Mappa dei centri di Sperimentazione Clinica
Pricing and reimbursement
Pricing and reimbursement
Negotiation and reimbursement
Economic evaluations
Monitoring Registers
AIFA Notes
Lists of Class A and Class H medicinal products
Innovative medicinal products
Transparency Lists
Consumption and pharmaceutical expenditure
Consumption and pharmaceutical expenditure
The Medicines Utilization Monitoring Centre (OsMed)
Governance of pharmaceutical expenditure
Monitoring pharmaceutical expenditure
Innovation and planning
Innovation and planning
Innovation and scientific advice
Horizon scanning
Information and communication
Information and communication
FarmaciLine
Medical and scientific information
FAQ
Publications
Communication campaigns
Eventi AIFA
Scientific Seminars
Press releases
Dossier AIFA
Mobile APP AIFA
APP Firstline AIFA - Antibiotici
ABC della Ricerca Clinica
Presentations and speeches
Public consultations and documents
Documents shared with scientific communities
Calendario eventi
Archivio
AIFA data
AIFA data
OsMed Data
Open Data
Companies Section
Companies Section
Requests for authorisation of conferences and meetings
Payment of fees and annual duties
MA Electronic invoicing
Application for reimbursement and pricing
Access information
Notifica concessionari di vendita
Comunicazione prima commercializzazione
Open governance
Open governance
Disposizioni Generali
Organizzazione
Consulenti e collaboratori
Personale
Bandi di Concorso
Performance
Enti controllati
Attività e procedimenti
Provvedimenti
Bandi di gara e contratti
Sovvenzioni, contributi, sussidi, vantaggi economici
Bilanci
Beni immobili e gestione patrimonio
Controlli e rilievi sull'Amministrazione
Servizi Erogati
Pagamenti dell'Amministrazione
Opere pubbliche
Pianificazione e governo del territorio
Informazioni ambientali
Interventi straordinari di emergenza
Altri Contenuti
Monitoring Registers
Monitoring Registers
The AIFA Monitoring Registers platform is an IT system that allows access to treatment in a homogeneous manner throughout the country. This is done through the control of prescriptive appropriateness. The system, co-managed with the Regions, also allows the planning and use of medicinal products subject to monitoring on the territory, controlling their expenditure. The Monitoring Registers Office manages the entire regulatory and scientific part preparatory to the online implementation of the Registers.
Monitoring Registers have a variety of functions but are essentially an administrative control modality that cannot interfere with patient care. Any IT blocks in the Registers do not justify in any way the delay or the impediment of clinical treatments which should always be guaranteed. Patient care always has priority over everything.
Monitoring Registers
How to use
The inclusion of a medicinal product in a Monitoring Register takes place after obtaining the marketing authorisation, or after the authorisation of an extension of its therapeutic indications. In some particular cases, the Registers also monitor the medicines reimbursed by the NHS pursuant to Law 648/96, i.e. before they are placed on the market.
AIFA Registers: legislation
Law No. 135 of 7 August 2012 recognised the Monitoring Registers as an integral part of the Information System of the NHS (art.15, paragraph 10), while further subsequent regulations (Law 125/2015; Law 232/2016; Law 205/2017) have assigned to the Registers functions of evaluating the effectiveness of the medicinal product for the purpose of renegotiation, and of controlling expenditure for innovative medicines and for avoidable costs in health care.
The AIFA Registers and the Regions
The AIFA Registers attribute a very important role to the Regions in the management of the support infrastructure, allowing intervention also in the authorisation system of the prescribing centers. In fact, the Health Directors (Direttori Sanitari) are authorised and, in turn, authorise medical users and pharmacists to use the platform.
The management network
The management of the register platform is organised through a network that includes approximately 3,500 health structures, 52 regional managers, 963 Health Directors, 32,857 doctors and 2,318 pharmacists. This network allows the Regions to regulate the organisation of pharmaceutical assistance on the territory. Currently, 49 pharmaceutical companies have at least one monitoring register managed by the AIFA platform. Companies interact with individual pharmacies through a profile defined on the platform, providing for the fulfillment of the conditional reimbursement agreements (Managed Entry Agreements, MEA), stipulated in the negotiation.
The different models of MEA and their application
AIFA has provided an advanced application of the different MEA models. According to an international taxonomy, these can be divided into two main categories: 1) Performance-Based Risk sharing schemes, outcome-based risk sharing agreements and 2) Financial based schemes, purely financial agreements. The first category includes the Payment by result (PbR), Risk sharing (RS) and Success fee (SF) agreements, while the second includes Cost sharing (CS) and Capping agreements. Cost sharing, generally adopted when there are more reliable data on the efficacy and safety of the medicine, provides a discount on the price of the first cycles of therapy for all patients eligible for treatment, as identified by the Summary of Product Characteristics. The risk sharing model, on the contrary, provides for a discount applicable only to patients who do not respond to treatment. The Payment by Result extends the RS modalities with the full reimbursement by the pharmaceutical company for all patients who do not respond to treatment (payback by pharmaceutical companies of 100% of therapeutic failures). This modality is usually used in the event that the benefit/risk ratio of the medicinal products presents a greater degree of uncertainty and requires a definition of the non-response based on the evidence available from the pivotal clinical trials. The Success fee provides that the NHS initially obtains the medicine from the owner company free of charge and, only after evaluating the response to treatment and in the event of therapeutic success, will remunerate the corresponding dispensed packs. Finally, the Capping agreement provides that the pharmaceutical company is responsible for dispensing the medicinal product after the quantities established by the negotiation agreement are exceeded.
Quick access to potentially health priority medicines
Another important element in the enhancement of the Monitoring Registers is the need to ensure rapid access to potentially priority medicines for health protection. This need must necessarily be balanced by reimbursement strategies that allow the NHS not to waste the limited economic resources available, especially in the case of high-cost medicines. The role of the Registers becomes all the more priority in the regulatory context the more the object of the assessment concerns a recently authorised medicinal product, whose benefit/risk ratio, although positive, is not fully defined or can significantly change depending on the way it is used. of use. On the other hand, in the case of authorization of an extension of the therapeutic indication of a medicinal product already placed on the market, the Registers make it possible to ensure that the use of the medicine complies strictly with the new indication. In fact, most of the medicines included in the AIFA Registers come from a centralized authorisation (often accelerated and/or conditioned) and mainly relate to biological and/or high-cost medicines for the NHS. The establishment and implementation of a Register provide, first and foremost, the identification of specific indicators of predictability of the response to treatment and allow an efficient delimitation of patient subpopulations who can obtain the maximum benefit from the medicinal product. The selection of the indicator and its measurement with respect to the outcome of the treatment is a process carried out within AIFA Advisory Committees (CTS and CPR), together with the assessments of the economic implications related to the authorisation of the medicinal product.
EXPAND ALL
Linee guida
Criteri di istituzione del monitoraggio tramite registri AIFA [1.09 Mb] [PDF] >
Updates
24/11/2025 -
Hepatitis C: update of 27 November 2025 concerning enrolled patients
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
29/10/2025 -
Hepatitis C: update of 27 October 2025 concerning enrolled patients
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
20/10/2025 -
Hepatitis C: update of 20 October 2025 concerning enrolled patients
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
ALL NOTICES
Pricing and reimbursement
Negotiation and reimbursement
Economic evaluations
Monitoring Registers
Access to system
Health facilities authorised by regional approvers
AIFA Registries
Analysis of monitoring registries
Update on hepatitis C
Registry archive
AIFA Notes
Lists of Class A and Class H medicinal products
Innovative medicinal products
Transparency Lists
Share
Archive
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Comunicazioni Managed Entry Agreements (MEA)
Nested Applications
Highlights
21/04/2026 - Medicine Use: 2024 Regional Reports Now Available Online
17/04/2026 - From one-size-fits-all treatments to personalised care: the revolution in precision medicine
ALL NEWS
ALL NEWS
News
21/04/2026
Medicine Use: 2024 Regional Reports Now Available Online
15/04/2026
AIFA updates the Transparency Lists
13/04/2026
Medicine Shortage Communication on Endoxan (ciclofosfamide)
All news
Nested Applications
Monitoring Registers Office
Monitoring Registers Office
Dirigente ad interim: Pierluigi Russo
p.russo@aifa.gov.it
Contacts
helpdesk@aifa.gov.it
Address reserved for assistance requests by clinical users and pharmacists for changes or clarifications relating to the monitoring forms of AIFA registries
registri.regioni@aifa.gov.it
Address reserved only for Regional contact persons to send questions relating to, i.e., regional qualifications of health facilities and to use of SAS reports
registri.aziende@aifa.gov.it
Address reserved only for Pharmaceutical companies' contact persons to send questions strictly related to their role and to use of SAS reports
Cookie Bar
Footer
The agency
Home Page
FarmaciLine
User participation and satisfaction
Citizens' access
Modulistica
Open governance
Acts of notification
Legal notification
TrovaNormeFarmaco
Competition notices
Tenders and contracts
Contacts
Via del Tritone, 181 00187 Roma
Contacts
Certified e-mail (PEC) contacts
VAT number: 08703841000
Tax code: 97345810580
IPA AIFA code: aifa_rm
IPA UCB code: UFE1TR
FOLLOW US ON
label.button.spotify
Bluesky
FEED RSS
Feed Rss
Cookie management
Sezione Link Utili
Legal notice
Social Media Policy
Dichiarazione di accessibilità
Web accessibility
Website statistics
Online services
go to beginning of content